Clene Inc (CLNN): Rasio kapitalisasi marang pendapatan
The development of nanotherapy involves immense risks and a fierce battle for leadership in sclerosis treatment for Clene Inc. (CLNN). The price-to-sales ratio helps identify asset overbought conditions in a timely manner, while the 234.60 metric serves as the baseline indicator. The unique drug CNM-Au8 provides neurons with energy; however, a critical liquidity deficit for regulatory approval requires management to urgently seek capital.
Rincian metrik lan analitis perusahaan Clene Inc. (CLNN)
- rega lan prakiraan konsensus rega:
- data kapitalisasi bursa:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Clene Inc.|CLNN - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas clene.com|CLNN - Utang perusahaan|Rasio utang marang nilai buku Clene Nanomedicine|CLNN - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Clene|Rasio likuiditas darurat clene.com
- data bathi bisnis lan rasio investasi:
CLNN - Bathi resik|Bathi resik sing dikarepake Clene Inc.|CLNN - Koefisien rega marang bathi|Pangali Forward P/E clene.com|CLNN - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Clene Nanomedicine|CLNN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Clene|CLNN - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan clene.com|CLNN - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Clene Inc.
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis fundamental perusahaan:Clene Inc (CLNN)
Clene Inc. is investing in a highly qualified staff of physicists and neurobiologists to develop multiple sclerosis therapies. The capitalization of these R&D assets correlates with sales volume, forming the 234.60 ratio. This metric measures the market value of a single unit of revenue, allowing for an assessment of whether the business is overvalued or undervalued. The price-to-sales dynamics help investors compare the current value of the company with its historical fundamental basis.
Pesaing Clene Inc.
Koefisien rega marang pendapatan biogen.com|Rasio rega marang pendapatan Neurocrine Biosciences, Inc. NBIX|RGC: Rasio kapitalisasi marang pendapatan|Axsome Therapeutics Inc - Multiplikator P/S|ACADIA Corp (ACAD) - Kapitalisasi marang pendapatan|XENE (Xenon Pharmaceuticals) - Kapitalisasi marang pendapatan|VKTX - Koefisien rega marang pendapatan|SUPN (Supernus) - Multiplikator P/S|Kapitalisasi marang pendapatan Catalyst Pharma (CPRX)|Rasio rega marang pendapatan Denali Therapeutics Inc (DNLI)|Rasio rega marang pendapatan HRMY (Harmony Corp)|Rasio rega marang pendapatan Biohaven Ltd. BHVN|AMLX: Rasio kapitalisasi marang pendapatan|TRVI - Rasio rega marang pendapatan|PRAX (Praxis Precision Medicines Inc) - Rasio kapitalisasi marang pendapatan|Anavex Corp (AVXL) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan CBLL|PRTA (Prothena Biosciences) - Multiplikator P/S|Rega marang dodolan Alector Therapeutics ALEC|Kapitalisasi marang pendapatan ANNX (Annexon)|Multiplikator P/S omeros.com (OMER)|Rasio rega marang pendapatan Neurogene Corp NGNE|Rasio kapitalisasi pasar marang pendapatan ACIU|VYGR - Rasio rega marang pendapatan|Rega marang dodolan neumoratx.com|SCLX: Multiplikator P/S|Kapitalisasi marang pendapatan Tevogen Bio Holdings Inc.|Rasio rega marang pendapatan Alpha Cognition Inc|Rasio rega marang pendapatan CGTX|Multiplikator P/S IKT|SAVA - Rega marang dodolan|Rasio rega marang pendapatan Assertio ASRT|COYA: Rasio kapitalisasi marang pendapatan|VistaGen Therapeutics Inc - Multiplikator P/S|Rega marang dodolan Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals) - Kapitalisasi marang pendapatan|cervomed.com - Rasio kapitalisasi pasar marang pendapatan|ATHE (Alterity Therapeutics Ltd.) - Multiplikator P/S|PepGen Corp (PEPG) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Jupiter Neurosciences (JUNS)|Relmada Corp - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ANVS (Annovis Bio, Inc.)|GRCE - Kapitalisasi marang pendapatan|AIFF: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Klotho Neurosciences Inc KLTO|NRSN: Multiplikator P/S|Kapitalisasi marang pendapatan Reviva Pharmaceuticals, Inc.|Rasio rega marang pendapatan MetaVia Inc.|Rasio rega marang pendapatan NRXS|Rasio rega marang pendapatan Helius Medical (HSDT)|passagebio.com - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Neuphoria Therapeutics NEUP|NERV: Rasio kapitalisasi marang pendapatan|ATHA - Rasio rega marang pendapatan|ADXN (addextherapeutics.com) - Rasio kapitalisasi marang pendapatan|ALZN: Multiplikator P/S|Rega marang dodolan Cyclerion Therapeutics, Inc. (CYCN)|Kapitalisasi marang pendapatan PTIX|Multiplikator P/S Pasithea|Rasio rega marang pendapatan Cortigent, Inc. (CRGT)|ATXI (avenuetx.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan BrainStorm Cell Therapeutics BCLI|Cara Therapeutics Inc. (CARA) - Rega marang dodolan|Chromocell Therapeutics Corporation - Multiplikator P/S|Eliem Therapeutics (ELYM) - Kapitalisasi marang pendapatan|intracellulartherapies.com (ITCI) - Rasio rega marang pendapatan|LBPH (longboardpharma.com) - Rasio rega marang pendapatan|MRNS (Marinus Pharmaceuticals, Inc.) - Multiplikator P/S|Rega marang dodolan NKGen Biotech Inc NKGN|Rasio rega marang pendapatan NeuroBo (NRBO)|Sage Therapeutics Inc - Rasio kapitalisasi marang pendapatan|Multiplikator P/S SNPX (Synaptogenix, Inc.)|trevena.com (TRVN) - Rega marang dodolan|VIGL: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan WENA (anewmeds.com)|CERE: Multiplikator P/S
